Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort.
Gagliardini R, De Benedittis S, Tavelli A, Lapadula G, Mazzotta V, Bruzzesi E, Cervo A, Carrozzo G, Saracino A, Rusconi S, Marchetti G, Ceccherini-Silberstein F, Antinori A, d'Arminio Monforte A, Muccini C; Icona Foundation Study Group. Gagliardini R, et al. J Antimicrob Chemother. 2025 Jun 17:dkaf184. doi: 10.1093/jac/dkaf184. Online ahead of print. J Antimicrob Chemother. 2025. PMID: 40570134
Switching to bictegravir/emtricitabine/tenofovir alafenamide from efavirenz/emtricitabine/tenofovir disoproxil in virologically suppressed people with HIV: findings from a non-randomized clinical trial (EBONY study).
Gagliardini R, Camici M, Lanini S, Bellagamba R, Ottou S, Plazzi MM, Vergori A, Mazzotta V, Mondi A, Fusto M, Paulicelli J, Tempestilli M, Pinnetti C, Grilli E, Mastrorosa I, De Zottis F, Duca GD, Antinori A. Gagliardini R, et al. Among authors: mastrorosa i. Int J Infect Dis. 2025 Jun 18;158:107961. doi: 10.1016/j.ijid.2025.107961. Online ahead of print. Int J Infect Dis. 2025. PMID: 40541768 Free article.
Comparative Effectiveness of Antiviral Agents and Monoclonal Antibodies for Early SARS-CoV-2 Therapy in Immunocompromised Patients: A Multicenter Retrospective Cohort Study (March 2021-March 2022).
Vita S, Maffongelli G, Bartoli TA, Benvenuto D, Marocco R, Rosati S, Mazzotta V, Del Borgo C, Mastrorosa I, De Marco P, D'Abramo A, Maggi F, Antinori A, Lichtner M, Nicastri E, Group C. Vita S, et al. Among authors: mastrorosa i. Microorganisms. 2025 May 6;13(5):1076. doi: 10.3390/microorganisms13051076. Microorganisms. 2025. PMID: 40431249 Free PMC article.
Comparative Analysis of Early COVID-19 Treatment Efficacy in a Multicentric Regional Cohort in Italy: Emulation of a Series of Target Trials.
Mazzotta V, Lepri AC, Del Borgo C, Lanini S, Meschi S, Garattini S, Rosati S, Siciliano V, Vergori A, Coppola L, Falletta A, Carraro A, Gramigna G, Oliva A, Matteini E, Gasperin A, Giannico G, Mastrorosa I, Matusali G, D'Abramo A, Marocco R, Milozzi E, Cerva C, Gavaruzzi F, Rueca M, Cimaglia C, Piselli P, Fantoni M, Girardi E, Sarmati L, Mastroianni CM, Andreoni M, Torti C, Nicastri E, Maggi F, Lichtner M, Antinori A; Early Treatment for COVID‐19 Lazio Study Group. Mazzotta V, et al. Among authors: mastrorosa i. J Med Virol. 2025 May;97(5):e70379. doi: 10.1002/jmv.70379. J Med Virol. 2025. PMID: 40326978 Free PMC article.
Safety and effectiveness of switch to bictegravir/emtricitabine/tenofovir alafenamide following dual regimen therapy in people with HIV: Insights from the Icona cohort.
De Vito A, Tavelli A, Cozzi-Lepri A, Giacomelli A, Rossotti R, Ponta G, Bobbio N, Ianniello A, Cingolani A, Madeddu G, Antinori A, d'Arminio Monforte A; ICONA Foundation Study Group. De Vito A, et al. HIV Med. 2025 Jun;26(6):970-977. doi: 10.1111/hiv.70037. Epub 2025 Apr 28. HIV Med. 2025. PMID: 40296167 Free PMC article.
Innate and SARS-CoV-2 specific adaptive immune response kinetic in neutralizing monoclonal antibody successfully treated COVID-19 patients.
Casetti R, Sacchi A, Mazzotta V, Cristofanelli F, Grassi G, Gili S, Cimini E, Notari S, Bordoni V, Mastrorosa I, Giancola ML, Vergori A, Tempestilli M, Vita S, Mariotti D, Rosati S, Lalle E, Meschi S, Colavita F, Garbuglia AR, Girardi E, Nicastri E, Antinori A, Agrati C. Casetti R, et al. Among authors: mastrorosa i. Int Immunopharmacol. 2025 Feb 20;148:113934. doi: 10.1016/j.intimp.2024.113934. Epub 2025 Jan 19. Int Immunopharmacol. 2025. PMID: 39832460
Effectiveness and Tolerability of DOR/3TC/TDF in Experienced People with HIV Switching from RPV/FTC/TDF: A Retrospective, Single Center Cohort Study.
Cicalini S, Lanini S, Gagliardini R, Bellagamba R, Vergori A, Mastrorosa I, Mazzotta V, Esvan R, Plazzi MM, Ottou S, Grilli E, De Zottis F, Fusto M, Paulicelli J, Antinori A. Cicalini S, et al. Among authors: mastrorosa i. Pharmaceuticals (Basel). 2024 Dec 17;17(12):1706. doi: 10.3390/ph17121706. Pharmaceuticals (Basel). 2024. PMID: 39770548 Free PMC article.
Incidence and predictors of clinical failure after early treatment for mild-to-moderate COVID-19 in high-risk individuals: A multicentric cohort study.
Mastrorosa I, Lepri AC, Borgo CD, Rosati S, Rueca M, Sarmati L, Mastroianni C, Fantoni M, Maggi F, Nicastri E, Girardi E, Lichtner M, Antinori A, Mazzotta V; Early Treatment for COVID‐19 Lazio Study Group. Mastrorosa I, et al. J Intern Med. 2025 Mar;297(3):328-334. doi: 10.1111/joim.20030. Epub 2024 Nov 13. J Intern Med. 2025. PMID: 39537383 Free PMC article.
55 results